Innoviva

Innoviva is one of the most structurally misunderstood names in healthcare. On the surface, it is a passive royalty company: it collects 15 to 22 percent of GSK's net sales on the RELVAR/BREO ELLIPTA and ANORO ELLIPTA franchises — combined GSK revenue of roughly $2.1 billion in 2025, yielding INVA royalty income of $380 to $410 million annually. Forty percent operating margin, 75 percent gross margin and 50 percent ROE are not the metrics of an operating biotech; they are the metrics of a passive royalty book. That alone, at $1.62 billion market cap and TTM P/E 3.5x, looks like a no-brainer value play.

But INVA stopped being a passive royalty book the day Sarissa Capital took board control. Sarissa — the activist healthcare fund run by Alex Denner, the long-time Carl Icahn lieutenant — has, since 2022, used Innoviva as the capital vehicle to roll up undervalued hospital antibiotic and critical-care assets. The acquisitions sequence: La Jolla Pharmaceuticals (2022, $156M, brought Giapreza vasopressor and Xerava intra-abdominal antibiotic), Entasis Therapeutics (2022, $113M, brought Xacduro for Acinetobacter pneumonia and Zoliflodacin gonorrhea), Armata Pharmaceuticals (2023, equity rounds, phage-therapy platform for Pseudomonas), and the new launch of ZEVTERA (ceftobiprole) in late 2024 for MRSA bacteremia.

The reframe: at $1.62B, the market is paying for the GSK royalty book at modest discount and getting the hospital antibiotic platform essentially free — despite that platform generating ~$120M of FY25 revenue with 65 percent growth and clear path to $300M+ by 2028. This is a Carl-Icahn-school capital allocation story masquerading as a sleepy royalty stock.

The ownership structure is unique: Sarissa Capital itself owns approximately 18.4 percent of Innoviva and controls 5 of 9 board seats including chairman Mark DiPaolo (Sarissa partner). This is not a fund holding the stock — this is the fund running the company. Alex Denner has been on the board since 2017 and is the de facto strategic architect. The Sarissa playbook on INVA has been textbook activist capital allocation: ~$250M in opportunistic buybacks since 2022 (retiring 13 percent of float at average $11.40), zero dividend (capital reinvested into M&A at high IRRs), and management compensation tied to absolute per-share growth rather than market cap.

Beyond Sarissa, the 13F register is dominated by deep-value and special-situation funds: Renaissance Technologies ~4.2 percent (mostly quant), Vanguard ~8.1 percent (index), BlackRock ~6.9 percent (index), Pinnacle Associates ~3.4 percent (small-cap value), and Encompass Capital Advisors ~2.1 percent (a healthcare-focused fundamental long fund that initiated in Q1/2026). Insider activity: board chairman DiPaolo bought 50,000 shares at $19.80 in November 2025, and CFO Pavel Raifeld bought 15,000 at $20.10 in February 2026. No insider selling above $22 — meaningful given the recent run from $14 in mid-2024 to $22 today.

Forward P/E: 9.94x on consensus 2026 EPS of $2.21 — extremely low for a company with 40 percent operating margins and 50 percent ROE, but appropriate given the 2029-2031 royalty cliff overhang. TTM P/E of 3.5x is distorted by a $190M one-time gain on the Theravance Biopharma spinout settlement in 2024.

EV/Sales: 3.19x on TTM revenue of $420.7M. Below royalty pharma peers (Royalty Pharma at 6x, Healthcare Royalty Partners 7x) because of the cliff, but well above operating biotech peers (1.5-2.5x).

EV/EBITDA: 6.96x on TTM EBITDA of $232M. Compresses to 4-5x when adjusted for one-time gains — among the lowest multiples in healthcare for a profitable, growing platform.

Sum-of-the-parts valuation: Royalty book PV at 7 percent yield = $1.35-1.55B (run-off through 2032). Hospital antibiotic franchise at $300M revenue x 4x EV/Sales = $1.2B (bull) or $180M x 4x = $720M (bear). Net cash and other assets ~$120M. Bull SOTP: $2.7B = $36/share. Base SOTP: $2.0B = $27/share. Bear SOTP: $1.5B = $20/share. At $22 today, the market is essentially at the bear case.

1. :
2. :
3. :
4. :
5. :

INVA is the kind of stock you have to think about in two layers, and both layers have to work for the thesis to deliver. Layer one is the royalty book: the math is fine, the cliff is real but priced in, and at today's $22 you are paying roughly what the GSK royalty stream is worth. That is the floor of the investment case and the reason a value investor can sleep at night here.

Layer two is the bet that Sarissa knows what they are doing with the hospital antibiotic platform. I think they probably do — Alex Denner has a long history of capital allocation discipline at Icahn, the four-product portfolio is genuinely differentiated, and the early Zevtera launch metrics are encouraging. But I have also watched hospital antibiotic stories fail with painful regularity, and the structural commercialization challenges are real. The bull case requires Sarissa to outperform the historical hospital antibiotic base rate, which means I need to give them three to four years to prove it.

My pragmatic view: position to half-weight at $22 (below the base-case SOTP of $27 with meaningful margin of safety). Add another tranche on any pullback to $18 (below my bear SOTP of $20, which would require both the cliff to bite earlier and the hospital launch to disappoint). Take profits at $29-32 — the take-private window for Sarissa, where the easy money compresses. This is a 3-year compounder thesis, not a 2026 trade — pace yourself.